Enroll in Research > Research Search & Enroll Tool > Talazoparib in Treating Patients With Recurrent, Advanced, or Metastatic Cancers and Inherited or Acquired Gene Mutations
Talazoparib in Treating Patients With Recurrent, Advanced, or Metastatic Cancers and Inherited or Acquired Gene Mutations

Talazoparib in Treating Patients With Recurrent, Advanced, or Metastatic Cancers and Inherited or Acquired Gene Mutations

Clinicaltrials.gov identifier:
NCT02286687


Study Contact Information:

Contact: Dr. Sarina A. Piha-Paul by phone: 713-563-1930 or email 


Talazoparib in Treating Patients With Recurrent, Advanced, or Metastatic Cancers and Inherited or Acquired Gene Mutations

About the Study

This study will look at how well the talazoparib works in treating patients with cancers that have returned after a period of improvement, do not respond to treatment, or have spread to other parts of the body, and have inherited mutations or tumor mutations in or other specific genes. NOTE: This study is no longer enrolling patients. 

Type of Study

This is an , single arm study.

  • In an study, participants will know which medication they are receiving.     
  • In a single-group assignment study, all study participants will receive the same therapy.

What the Study Entails

  • Participants will receive orally once per day. Participants will remain on the medication as long as their cancer doesn't progress and they don't experience unacceptable side effects. 
  • Participants are followed up at 30 days and then every 12 weeks for 1 year.

Study Site

Houston, TX
M D Anderson Cancer Center
Contact: Dr. Sarina A. Piha-Paul by phone: 713-563-1930     

This Study is Open To:

NOTE: This study is no longer enrolling patients. 

This Study is Not Open To:

NOTE: This study is no longer enrolling patients.